$SKYW

Is It Worth Investing in SkyWest (SKYW) Based on Wall Street's Bullish Views?

Zacks Investment Research discusses SkyWest (SKYW) analyst sentiment, citing an average brokerage recommendation (ABR) of 1.86 on a 1 to 5 scale based on seven firms, with four Strong Buys (57.1%). It says the Zacks Consensus Estimate for current-year EPS fell 1% to $10.88 and assigns a Zacks Rank #4 (Sell).

Original reporting
Published Jul 24, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 25, 2026, 2:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is It Worth Investing in SkyWest (SKYW) Based on Wall Street's Bullish Views? — source image
Decision brief

The 30-second read

$SKYWBearishLow
01

Why it matters

For SkyWest, the actionable signal is the direction of earnings estimate revisions: Zacks Consensus Estimate fell 1% to $10.88 and the stock is assigned Zacks Rank #4 (Sell).

02

Market read

The piece frames near-term risk as coming from worsening EPS estimate revisions, despite ABR leaning toward buy.

03

What to watch

The article does not provide any new operational or financial disclosure (no guidance, earnings print, or contract). Traders should verify whether the estimate declines reflect temporary items versus durable demand/cost changes.

Relevance 4/10Novelty 4/10Timing: positioning ahead of near-term earnings estimate revision trend

Background

The article discusses how brokerage analyst ratings (ABR) can be biased and contrasts them with Zacks Rank, which is driven by earnings estimate revisions.

Company-level read

Ticker impact

$SKYWBearishMedium confidence
Context

Article cites SkyWest’s ABR of 1.86 (buy-equivalent) but also notes Zacks Rank #4 (Sell) tied to declining EPS consensus.

Expected impact

Bias toward downside or underperformance until earnings-estimate revisions stabilize.

Evidence & confidence

The newest concrete datapoints are ABR (1.86) and Zacks Consensus Estimate down 1% to $10.88, alongside a Zacks Rank #4 (Sell) driven by EPS estimate revisions.

Market effects

Limited read-through to the airline/regional carrier sector because the piece is primarily about analyst-rating methodology and SkyWest’s estimate revisions.

No specific regional market catalyst described beyond company-specific earnings estimate changes.

No global macro or cross-border event tied to SkyWest in the text.

Counterpoint

ABR is still buy-equivalent (1.86) with 4 of 7 Strong Buy calls, so the stock could be supported if the market discounts the Zacks-driven bearishness.

Key entities

  • SkyWest, Inc.

    Subject of the article, with ABR 1.86 and Zacks Rank #4 (Sell) based on earnings estimate revisions.

  • Zacks Investment Research

    Provides Zacks Rank and Zacks Consensus Estimate figures cited in the article.

Related articles

$SKYWMedAI 8/10

SKYWEST INC (SKYW): Results of Operations and Financial Condition

SKYWEST INC (SKYW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 skyw-20260723xex99d1.htm EX-99.1 Exhibit 99.1 ​ NEWS RELEASE ​ ​ ​ ​ ​ CONTACT: Investor Relations Corporate Communications ​ 435.634.3200 435.634.3553 ​ Investor.relations@skywest.com corporate.communications@skywest.com ​ ​ SkyWest, Inc. Announces Second Quarter 2026

$SKYWMed

Court upholds SkyWest harassment verdict, backs punitive damages against airline

A Fifth Circuit appeals court upheld a sexual harassment verdict and punitive damages against SkyWest Airlines, saying its internal investigation was inadequate. The EEOC brought the Title VII case for a parts clerk at Dallas-Fort Worth International Airport. The court found evidence of supervisor malice or reckless indifference and ruled plaintiffs need not mitigate emotional-distress damages.

$SKYWMedAI 8/10

SkyWest Stock Falls After Goldman Sachs Downgrade

SkyWest (SKYW) shares fell over 1.5% after Goldman Sachs downgraded the regional airline to Neutral from Buy, citing concerns that slower aircraft utilization could pressure earnings. Goldman cut its 2026 price target to $108 from $126, lowering forecast block-hour growth. It also raised 3Q/4Q 2026 industry profit estimates, citing resilient travel demand.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.